This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Buy Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG), owing to product launches and the performance of segments.
Neogen (NEOG) to Offer Biosecurity Products With New Pact
by Zacks Equity Research
Neogen will be able to highlight its biosecurity and horse health products, like the COMPANION range of cleansers and disinfection solutions, through the latest collaboration.
Neogen (NEOG) Unveils New Assay for Walnut Allergens Detection
by Zacks Equity Research
Neogen's (NEOG) Veratox VIP for Walnut allergy test displays robust performance across sample types while keeping the Veratox product line's simple testing approach.
Abbott (ABT) Up 5.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen's (NEOG) Innovation Aids, Currency Headwind Stays
by Zacks Equity Research
Neogen (NEOG) is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets.
Neogen (NEOG) Up 3.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen's (NEOG) Q1 Earnings Miss Estimates, Margins Rise
by Zacks Equity Research
Neogen's (NEOG) Q1 Animal Safety business experiences continued destocking, with channel inventory levels reaching multi-year lows.
Company News for Oct 11, 2023
by Zacks Equity Research
Companies in The News Are: PEP,NEOG,PLTR,TFC
Neogen (NEOG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Neogen (NEOG) give a sense of how the business performed in the quarter ended August 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Here's Why Neogen (NEOG) is Poised for a Turnaround After Losing -14.43% in 4 Weeks
by Zacks Equity Research
Neogen (NEOG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neogen (NEOG) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -21.43% and 1.23%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG), led by progress in the Food Safety business and recent product launches.
Neogen (NEOG) Gains From Strong Segmental Sales, Innovation
by Zacks Equity Research
Within the biosecurity portfolio, Neogen (NEOG) continues to record solid growth in cleaners, disinfectants and rodenticides.
High Tide Inc. (HITI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
High Tide Inc. (HITI) delivered earnings and revenue surprises of 25% and 4.52%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
Down -12.39% in 4 Weeks, Here's Why Neogen (NEOG) Looks Ripe for a Turnaround
by Zacks Equity Research
Neogen (NEOG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool
by Zacks Equity Research
Neogen (NEOG) introduces the latest solution in the SureKill brand of products, SureKill Evolve SC.
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) on recent product launches.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Neogen (NEOG) Introduces New Genomic Data Management Tool
by Zacks Equity Research
Neogen's (NEOG) new Igenity Enhanced Dairy offers farmers valid data and assesses their herd's potential. It helps them make the most informed decisions.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
3 Medical Product Stocks Set to Outpace Q2 Earnings Estimates
by Indrajit Bandyopadhyay
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how NEOG, PDCO and DH are poised ahead of their earnings release.
Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Neogen (NEOG) Q4 fiscal 2023 results reflect core growth in both operating segments despite softening market conditions.
Molina (MOH) Q2 Earnings Beat on High Premiums, '23 View Raised
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results are aided by increased membership, and Medicaid and Medicare strength.
Neogen (NEOG) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 40% and 6.38%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?
Philips (PHG) Q2 Earnings Beat Estimates, Revenue Rise Y/Y
by Zacks Equity Research
Philips' (PHG) second-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.